Bionoid Pharma (Bionoid Pharma) EV-to-EBIT : -1.49 (As of Jun. 06, 2024)

Bionoid Pharma EV-to-EBIT Chart

Bionoid Pharma Quarterly Data
	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
EV-to-EBIT	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Bionoid Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Bionoid Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionoid Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bionoid Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bionoid Pharma's EV-to-EBIT falls into.

Bionoid Pharma EV-to-EBIT Calculation

Bionoid Pharma's EV-to-EBIT for today is calculated as:

Bionoid Pharma's current Enterprise Value is $13.50 Mil.
Bionoid Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionoid Pharma  (OTCPK:BINP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bionoid Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2011 is calculated as:

Bionoid Pharma's Enterprise Value for the quarter that ended in Mar. 2011 was $20.24 Mil.
Bionoid Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionoid Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bionoid Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionoid Pharma (Bionoid Pharma) Business Description